Skip to content

Bristol Myers Squibb made an announcement Friday regarding an FDA approval for patients with first-line metastatic NSCLC and PD-L1 ≥1%.

5/18/2020

Bristol Myers Squibb made an announcement Friday regarding an FDA approval for patients with first-line metastatic NSCLC and PD-L1 ≥1%. The press release can be accessed here

https://news.bms.com/press-release/corporatefinancial-news/us-food-and-drug-administration-approves-opdivo-nivolumab-ye-1

Powered By GrowthZone